Table 1.
List of neoadjuvant chemotherapy trials included in the 2005 ABC meta-analysis
| Author/year | No. patients | Stage | NC regimen | Definitive treatment | OS benefit |
|---|---|---|---|---|---|
| Wallace/199129 | 159 | T2–4NXM0 | Cisplatin 100 mg/m2 | 45–50 Gy in 22F 65 Gy in 22F + |
No |
| Raghavan/199130 | 96 | T2–4NXM0 | Cisplatin 70 mg/m2 | RC + pelvic lymphadenectomy | No |
| Martinez-Pineiro/199531 | 122 | T2–4ANX-2M0 | Cisplatin 100 mg/m2 | RC + pelvic lymphadenectomy | No |
| Malmstrom/199632 | 325 | T1 (grade3) T2–4ANXM0 |
Cisplatin 70 mg/m2 Doxorubicin 30 mg/m2 |
20 Gy in 5F + RC + pelvic lymphadenectomy |
Yes for T3–T4 (p=0.03) |
| Abol-Enein/199733 | 196 | T2–4ANXM0 | Carboplatin 300 mg/m2 Methotrexate 50 mg/m2 Vinblastine 4 mg/m2 |
RC + pelvic lymphadenectomy | Not reported |
| Bassi/199934 | 206 | T2–4N0M0 | Cisplatin 70 mg/m2 Methotrexate 30 mg/m2 Vinblastine 3 mg/m2 |
RC + pelvic lymphadenectomy | Not reported |
| International Collaboration/1999,7 updated 20118 | 976 | T2 (grade 3) T3–T4ANO,NXM0 |
Cisplatin 100 mg/m2 Vinblastine 4 mg/m2 Methotrexate 30 mg/m2 |
60 Gy in 30F (or) 20 Gy in 5F + RC (or) RC and pelvic lymphadenectomy | Yes on 2011 update (p=0.037) |
| Sherif/200235 | 317 | T2–4ANXM0 | Cisplatin 100 mg/m2 Methotrexate 250 mg/m2 |
RC + pelvic lymphadenectomy | No |
| Sengelov/200236 | 153 | T2–T4bN0NXM0 | Cisplatin 100 mg/m2 Methotrexate 250 mg/m2 |
60 Gy in 30F (or) RC | No (p=0.76) |
| Cortesi/unpublished | 171 | T2–4N0M0 | Cisplatin 70 mg/m2 Methotrexate 30 mg/m2 Vinblastine 3 mg/m2 Epirubicin 40 mg/m2 Methotrexate 30 mg/m2 |
RC | Not reported |
| Grossman/20039 | 317 | T2–T4ANXM0 | Vinblastine 3 mg/m2 Doxorubicin 30 mg/m2 Cisplatin 70 mg/m2 |
RC | No (p=0.06) |
ABC: advanced bladder cancer; NC: neoadjuvant chemotherapy; OS: overall survival; RC: radical cystectomy; F: fractions.